| Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. M Andersson, J Alvarez-Cermeno, G Bernardi, I Cogato, P Fredman, ... Journal of Neurology, Neurosurgery & Psychiatry 57 (8), 897-902, 1994 | 961 | 1994 |
| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 938 | 2018 |
| Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? F Licastro, S Pedrini, L Caputo, G Annoni, LJ Davis, C Ferri, V Casadei, ... Journal of neuroimmunology 103 (1), 97-102, 2000 | 489 | 2000 |
| Disease‐modifying therapies and coronavirus disease 2019 severity in multiple sclerosis MP Sormani, N De Rossi, I Schiavetti, L Carmisciano, C Cordioli, L Moiola, ... Annals of neurology 89 (4), 780-789, 2021 | 470 | 2021 |
| Association of early‐onset Alzheimer's disease with an interleukin‐1α gene polymorphism LME Grimaldi, VM Casadei, C Ferri, F Veglia, F Licastro, G Annoni, ... Annals of Neurology: Official Journal of the American Neurological …, 2000 | 460 | 2000 |
| Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial P Vermersch, A Czlonkowska, LME Grimaldi, C Confavreux, G Comi, ... Multiple Sclerosis Journal 20 (6), 705-716, 2014 | 391 | 2014 |
| Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open … R Kapoor, PR Ho, N Campbell, I Chang, A Deykin, F Forrestal, N Lucas, ... The Lancet Neurology 17 (5), 405-415, 2018 | 326 | 2018 |
| Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1α R Dominici, M Cattaneo, G Malferrari, D Archi, C Mariani, L Grimaldi, ... Immunogenetics 54, 82-86, 2002 | 237 | 2002 |
| Interleukin-6 gene alleles affect the risk of Alzheimer’s disease and levels of the cytokine in blood and brain F Licastro, LME Grimaldi, M Bonafè, C Martina, F Olivieri, L Cavallone, ... Neurobiology of aging 24 (7), 921-926, 2003 | 226 | 2003 |
| Elevated alpha–tumor necrosis factor levels in spinal fluid from HIV‐1–infected patients with central nervous system involvement LME Grimaldi, GV Martino, DM Franciotta, R Brustia, A Castagna, ... Annals of Neurology: Official Journal of the American Neurological …, 1991 | 217 | 1991 |
| Multiple sclerosis in children under 6 years of age M Ruggieri, A Polizzi, L Pavone, LME Grimaldi Neurology 53 (3), 478-478, 1999 | 214 | 1999 |
| Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy A Halliday, R Bulbulia, LH Bonati, J Chester, A Cradduck-Bamford, R Peto, ... The Lancet 398 (10305), 1065-1073, 2021 | 178 | 2021 |
| Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease D Lio, F Licastro, L Scola, M Chiappelli, LM Grimaldi, A Crivello, ... Genes & Immunity 4 (3), 234-238, 2003 | 165 | 2003 |
| Gene polymorphism affecting α1‐antichymotrypsin and interleukin‐1 plasma levels increases Alzheimer's disease risk F Licastro, S Pedrini, C Ferri, V Casadei, M Govoni, A Pession, FL Sciacca, ... Annals of neurology 48 (3), 388-391, 2000 | 160 | 2000 |
| Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial D Cadavid, M Mellion, R Hupperts, KR Edwards, PA Calabresi, J Drulović, ... The Lancet Neurology 18 (9), 845-856, 2019 | 156 | 2019 |
| Glucocorticoid-related genetic susceptibility for Alzheimer's disease DJF de Quervain, R Poirier, MA Wollmer, LME Grimaldi, M Tsolaki, ... Human molecular genetics 13 (1), 47-52, 2004 | 155 | 2004 |
| Efficacy of vitamin D3 as add-on therapy in patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double … J Smolders, R Hupperts, F Barkhof, LME Grimaldi, T Holmoy, J Killestein, ... Journal of the neurological sciences 311 (1-2), 44-49, 2011 | 143 | 2011 |
| Autoimmune protein S deficiency in a boy with severe thromboembolic disease A D'Angelo, PD Valle, L Crippa, E Pattarini, L Grimaldi, SV D'Angelo New England Journal of Medicine 328 (24), 1753-1757, 1993 | 140 | 1993 |
| Neuroinflammation and the genetics of Alzheimer’s disease: the search for a pro-inflammatory phenotype C Franceschi, S Valensin, F Lescai, F Olivieri, F Licastro, LME Grimaldi, ... Aging Clinical and Experimental Research 13, 163-170, 2001 | 139 | 2001 |
| Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS L Kappos, EW Radue, G Comi, X Montalban, H Butzkueven, H Wiendl, ... Neurology 85 (1), 29-39, 2015 | 135 | 2015 |
